Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab/Pomalidomide vs Carfilzomib/Pomalidomide/Dexamethasone in Early Relapse of Multiple Myeloma
NCT07463807Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2027
- Primary completion
- Mar 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Apr 2027; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07463807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463807.